Introduction
Hematopoietic toxicity produced by intensive treatment with many anticancer drugs limits their curative potential. The transfer and expression of drug resistance genes in normal blood cells may protect them from the toxic effect of chemotherapy and permit dose escalation to increase clinical efficacy. 1 Several investigators have inserted drug resistance genes into murine bone marrow cells to evaluate the potential of chemoprotection in mice. In these studies, the transplantation of hematopoietic cells transduced with the genes for multiple drug resistance (MDR), 2, 3 dihydrofolate reductase (DHFR), 4, 5 or O 6 -alkylguanine-DNA alkyltransferase (alkyltransferase) 6, 7 resulted in expression of these drug resistance genes and in some cases chemoprotection against the respective antineoplastic drugs. Clinical trials on chemoprotection of cancer patients with the introduction of the MDR gene into hematopoietic progenitor cells are presently under investigation. [8] [9] [10] [11] Our laboratory has been investigating the drug resist- ance gene, cytidine deaminase (CD), which codes for an enzyme that inactivates cytosine nucleoside analogues, such as cytosine arabinoside (Ara-C), 2Ј,2Ј-difluorodeoxycytidine (dFdC) and 5-aza-2Ј-deoxycytidine (5-AZA-CdR). 12, 13 Myelosuppression constitutes a major limiting factor for the utilization of high doses of these analogues in cancer therapy. [14] [15] [16] [17] In previous studies, we purified, cloned and expressed the human CD cDNA. 18 We demonstrated increased resistance to Ara-C, 19 ,20 dFdC and 5-AZA-CdR 21, 22 in murine fibroblasts following retroviral gene transfer of CD. In addition, transduction of normal murine bone marrow cells conferred in vitro chemoprotection to Ara-C. 20 In the present report, we likewise used MFG-CD retroviral virions to transduce murine bone marrow cells and then transplanted these into syngeneic mice that were lethally irradiated. Following treatment with Ara-C, we detected the presence of proviral CD and increased CD activity in various hematopoietic tissues, and signs of in vitro drug resistance to Ara-C.
Results
Hematopoietic cells from male mice were transduced with MFG-CD or MFG-LacZ virions ex vivo and then transplanted into irradiated female syngeneic mice.
Recipients were administered an Ara-C infusion at intervals of 6 or more weeks for three treatments. The peripheral blood was collected at 5 days after each Ara-C treatment. At 11 to 13 months after transplantation, the mice were killed and their blood, marrow and spleen analyzed for proviral integration and CD expression.
Detection of CD provirus in blood at different time intervals after transplantation To establish the presence in blood of the CD transgene at different times after bone marrow transplantation, the blood was examined by PCR (Table 1) . For these CD mice PCR analysis was performed on DNA isolated from blood collected 5 days after each cycle of Ara-C administered at intervals of 4-5, 6-8 and 8-10 months. The mice were killed at 11-13 months. Results showed a detectable CD provirus in at least 75% of the mice studied. The percentage of mice with CD positive blood did not diminish with time. CD proviral DNA was not detected in Lac mice (data not shown).
Detection of CD provirus in different tissues at 11-13 months after transplantation In order to obtain evidence of long-term engraftment of transduced cells in various hematopoietic tissues, PCR reactions were performed to detect CD provirus and Ychromosome. Figure 1 displays PCR analysis of genomic DNA from blood, bone marrow and spleen cells obtained at 11-13 months after transplantation. In seven out of nine mice, we detected the CD transgene in all three tissues. Of the other two mice, CD mouse No. 2 was positive for CD proviral DNA only in the bone marrow, whereas CD mouse No. 3 was positive in the spleen and blood. As expected, samples from Lac mice failed to yield a proviral CD signal; only Lac mouse No. 4 is included in Figure 1 .
An additional PCR reaction was performed to evaluate the engraftment of male donor hematopoietic cells into the female recipients by the demonstration of the presence of the Y-chromosome. We detected this DNA fragment in all the three tissues of every CD mouse examined ( Figure 1 ). This result further confirms that the MFG-CD positive PCR signals originated from the integrated CD gene in male donor marrow cells. Of the six Lac mice also analyzed, a positive signal for the Y-chromosome was observed in four mice (data not shown). The fact that two of the six Lac mice analyzed did not exhibit a Y- positive signal may reflect low efficiency of gene transfer, weak engraftment or shorter persistence of the MFGLacZ transduced cells. PCR detection of the ␤-globin gene was also performed to verify the quality of genomic DNA isolated from each tissue. The ␤-globin was easily detected in the blood, bone marrow and spleen of all CD and Lac mice tested.
Analysis of hematopoietic colonies for presence of CD provirus Genomic DNA was prepared from a single colony or pools of two to five colonies derived from bone marrow cells harvested from mice 11-13 months after transplantation. This DNA was used for PCR analysis for detection of CD provirus, Y-chromosome and ␤-globin gene (Table 2 ). In several assays of individual colonies from CD mouse Nos 6, 8 and 9, we observed the proviral CD in 44%, 20% and 50%, respectively, of the colonies analyzed. For the pooled colonies, the positive CD signal varied from 0 to 100% for CD mouse No. 1 and CD mice Nos 4 to 7. For mouse CD No. 6, which had the highest CD enzyme activity in marrow ( Figure 2 ), 100% of pooled colonies contained the CD proviral sequences, whereas we detected CD in 44% of the single colonies. For this mouse, 60% of individual colonies derived from spleen displayed positive PCR signals for MFG-CD (data not presented).
To determine the efficiency of engraftment of male donor cells, Y-chromosome screening was performed. For CD mouse No. 1 and CD mice Nos 4 to 7, at least 75% of pooled hematopoietic colonies scored positive by PCR for the Y-chromosome fragment. For CD mouse Nos 6 and 9, 100% and 80% of single colonies, respectively, displayed the positive Y signal. However, for CD mouse No. 8, even though we detected 20% MFG-CD positive colonies, we did not observe any Y-positive bands in the individual colonies. This occurrence was probably due to the very small amounts of DNA isolated from a single hematopoietic colony resulting in our performing PCR at the limit of detection which may have led to false negative results in some cases.
Expression of human CD enzyme activity in different tissues after transplantation CD enzyme activity was measured in various tissues to determine if the CD provirus was capable of expression at 11 to 13 months after transplantation of transduced hematopoietic cells. As depicted in Figure 2 , bone marrow cells of several CD mice exhibited increased levels of CD activity as compared with the mean value from five Lac mice. CD mouse No. 6 marrow cells displayed a striking Ͼ80-fold augmentation in enzyme activity when compared with Lac controls. Bone marrow cells from CD mouse Nos 1, 3, 4 and 8 showed a 2.9-to 5.4-fold higher CD activity than Lac mice. These differences of enzyme activity between Lac mice and CD mouse Nos 1, 3, 4, 6 and 8 were significant, P р 0.05 (Student's t test). For single colony analysis, DNA isolation was performed on an individual colony, and for each mouse, five to 10 different colonies were analyzed by PCR. For pooled colony analysis, DNA isolation was performed on a pool of two to five colonies, and for each mouse, three to six different pools were analyzed by PCR. In Figure 2 , analysis of the spleens of recipients of transduced marrow revealed that for several CD mice, the CD enzyme activity surpassed that of Lac mice. Notably, CD mouse Nos 6 and 8 showed a 20-and 8.0-fold increase, respectively, in CD activity as compared with control Lac mice. CD mouse Nos 1 and 7 showed a 2.2-and 3.3-fold elevation in CD activity, respectively, as compared to the activity in spleens from Lac mice, P р 0.05 (Student's t test). Analysis of the blood cells showed Ͼ100-fold increase in CD activity for CD mouse No. 6 when compared with control mice (Table 3) . CD mouse Nos 3 and 4 showed a five-and 10-fold rise in CD activity, respectively. Strikingly, CD mouse No. 6 displayed from 20-to 130-fold augmentation in CD enzyme activity in the different tissues analyzed when compared with the control Lac mice.
Figure 2 Expression of human CD enzyme activity in bone marrow
Clonogenic assay on marrow and spleen cells for Ara-C resistance In vitro clonogenic assays were performed to evaluate drug resistance to Ara-C in bone marrow and spleen cells collected from mice 11-13 months after transplantation. At an Ara-C concentration of 0.5 m, the clonogenic progenitor cells of several CD mice demonstrated a higher survival than those of Lac mice. A range of 2 to 6% survival in the presence of Ara-C was observed by clonogenic assays of marrow cells from CD mouse Nos 1, 3 and 4 as compared with less than 1% survival for marrow cells from Lac mice (Table 4) . Notably, the marrow cells from CD mouse No. 6 (which also displayed the highest CD enzyme activity) showed 29% survival in the presence of Ara-C. All the colonies that formed in presence of Ara-C from CD mouse No. 6 showed a positive PCR signal for MFG-CD (data not shown). For colonies generated from spleen cells, 23 and 17% survival in the pres- ence of Ara-C were noted for CD mouse Nos 4 and 6, respectively.
Discussion
The myelosuppression produced by many antineoplastic drugs has prevented the utilization of intensive doses which may improve antitumor response. For instance, the clinical effectiveness for the treatment of lung or breast cancer with cytosine nucleoside analogues, such as Ara-C 15 and the new promising agents, dFdC 16 and 5-AZACdR 17 is limited by their hematopoietic toxicity. The efficacy of chemotherapy with these analogues would be improved if their dose-dependent myelotoxicity could be circumvented. One way to overcome this serious sideeffect would be to overexpress the gene for CD in normal hematopoietic progenitor cells to render them drug resistant.
Cytidine deaminase can deaminate cytosine nucleoside analogues and thus catalyze their conversion to pharmacologically less active uracil derivatives. 12, 13 We have inserted the CD cDNA into the MFG retroviral plasmid expression vector. The cDNA for human CD contains only 438 bp 18 facilitating genetic manipulation. We succeeded in transfecting and, subsequently, transducing murine cells in vitro. 19, 20 The transduced fibroblast cells demonstrated significantly increased expression of CD proviral RNA and enzyme activity, as well as drug resistance to Ara-C. 20 In addition, in a separate study, we observed drug resistance in these cells to other cytosine nucleoside analogues, dFdC and 5-AZA-CdR. 21 , 22 We also reported that clonogenic murine hematopoietic cells transduced with CD showed resistance to Ara-C. 20 In this study, we demonstrate that CD-transduced bone marrow cells transplanted into mice can persist for more than 1 year and express CD. The persistence of the MFG-CD construct in many tissue samples after transplantation indicates the successful transduction of some pluripotent bone marrow cells capable of long-term engraftment. The detection of CD provirus by PCR in many hematopoietic colonies more than 1 year after transplantation indicates transduction and persistence of the transgene in hematopoietic progenitor cells that can survive in vivo and can form colonies in vitro.
For mouse CD No. 6, which showed the highest CD enzyme activity, 44% of individual colonies were found to be positive for MFG-CD provirus (Table 2 ). For this same mouse, 60% of single colonies derived from spleen displayed positive PCR signals for MFG-CD (data not presented).
The increased levels of CD enzyme activity observed in the bone marrow, spleen and blood in many mice when assayed at 11-13 months indicates long-term expression of the proviral CD gene. The low CD enzyme activity obtained in some of the tissue samples may be due to low transduction frequency and/or provirus inactivation possibly by de novo methylation of cytosine residues in the retroviral promoter for proviral CD. 23 Our results are in agreement with several studies utilizing other drug resistance genes that also showed long-term expression after transplantation of transduced cells into mice. [2] [3] [4] [5] [6] [7] Our investigation constitutes the first in vivo CD gene transfer study reported. The data presented here using the MFG-CD construct clearly demonstrate the feasibility of obtaining in vivo long-term persistence of CD and long-term expression of human CD in hematopoietic cells. We plan to transplant CD transduced marrow cells into tumor-bearing mice to determine if curability with cytosine nucleoside analogues can be obtained using chemoprotection as reported by Zhao et al 24 for the DHFR gene and methotrexate therapy. Future improvements in vectors to increase efficiency of transduction and expression of CD in human hematopoietic cells will facilitate the use of this gene for chemoprotection to increase the therapeutic effectiveness of cytosine nucleoside analogues in cancer therapy.
Materials and methods
Cell culture of murine fibroblasts GP+E-86 ecotropic retrovirus-packaging cells (A Bank, Columbia University, New York) 25 were grown in Dulbecco's modified essential medium (Canadian Life Technologies, Burlington, Ontario, Canada) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Wisent Technologies, St Bruno, Quebec, Canada) and 5 g/ml gentamicin (Canadian Life Technologies), and incubated at 37°C with 7% CO 2 .
Retroviral vector and virus-producing cell lines
The cDNA for human CD was cloned into the pMFG retroviral vector (R Mulligan, Harvard University, Cambridge, MA, USA) to yield the pMFG-CD construct, as we described previously. 19 The plasmid pMFG-CD was transfected into GP+E-86 packaging cells. Clone GP+E-86-CD3 was isolated and displayed elevated CD expression and Ara-C resistance. 19 This producer cell line had an estimated viral titer of approximately 4 × 10 5 infective particles/ml. 20 The pMFG-LacZ vector (R Mulligan) was similarly used to generate the clone GP+E-86-LacZ. Donor mice and transduction of bone marrow cells GP+E-86-CD3 and GP+E-86-LacZ cells were sublethally irradiated with 20 Gy (cobalt source) and plated at a density of 3 to 5 × 10 6 cells per 10 cm diameter tissue culture dish, 12 to 24 h preceding bone marrow transduction. Hematopoietic cells were harvested from the hind leg femurs and tibias of 7-to 21-week-old male C3H HeJ mice (Jackson Laboratories, Bar Harbor, ME, USA) 48 h after a single intraperitoneal injection of 150 mg/kg 5-fluorouracil (David Bull Laboratories, Vaudreuil, Quebec, Canada). Fresh nucleated marrow cells (3 to 5 × 10 6 cells) were layered on to each monolayer of irradiated virusproducing cells. Cocultures were incubated for 72 h in alpha minimal essential medium (Gibco, Grand Island, NY, USA) supplemented with 20% FBS, 10 mg/ml bovine serum albumin (Boehringer Mannheim, Laval, Quebec), 0.3 mg/ml iron-saturated human transferrin (Boehringer Mannheim), 5 g/ml gentamicin (Canadian Life Technologies), 4 g/ml polybrene (Sigma Chemical, St Louis, MO, USA), 10% conditioned medium from the WEHI-3B murine myelomonocytic cells 26 and 10% conditioned medium from the HTB-9 primary bladder carcinoma cell line. 27 Transplantation and recipients Following cocultivation, the nonadherent hematopoietic cells were carefully collected, concentrated by centrifugation, and 1 to 2 × 10 6 cells injected via the tail vein into irradiated female syngeneic recipient mice (Jackson Laboratories) exposed to 10.5 Gy irradiation 17-20 h earlier. Animals that received marrow transduced with MFG-CD were termed 'CD mice' whereas those that were transplanted with MFG-LacZ transduced cells were called 'Lac mice'. The transplanted mice were provided with 2.5 mg/ml neomycin in the drinking water starting 1 week before and until 4 weeks after transplantation.
Ara-C infusions and tissue acquisition
The mice were administered three cycles of Ara-C (Upjohn, Don Mills, Ontario, Canada) administered as a single 10 to 15 h infusion at a total dose of 75 to 110 mg/kg at intervals of 4 to 5, 6 to 8, and 8 to 10 months after transplantation. The i.v. infusions were performed as described previously. 28 Briefly, unanesthetized mice were placed in restraining cages (Scientific Products, Irvine, CA, USA) with a wood tongue blade taped to the bottom. A 25-gauge needle, attached to a butterfly and 5 cc syringe, was inserted into the lateral tail vein and immobilized to the wood blade by Transpore 3 M tape. The syringe containing sterile Ara-C in 0.45% NaCl was attached to a Harvard Model 975 infusion pump (South Natick, MA, USA) and the drug infused at a rate of 0.22 ml/h. Food pellets were placed in the restraining cage during the infusion. Five days after every treatment, peripheral blood was obtained from the tail vein. At 11 to 13 months after transplantation, nine CD mice and six Lac mice were killed to obtain the marrow and spleen. Blood was collected by cardiac puncture. These tissues were used for PCR analysis, CD enzyme activity measurements and clonogenic assays.
Clonogenic assay
Clonogenic assays were carried out using bone marrow and spleen cells. The latter cells were incubated for 7 min in 0.83% NH 4 Cl to hemolyze red blood cells. The cells from the mice were plated at 10 5 cells per dish (marrow) or 5 × 10 5 cells per dish (spleen) in RPMI 1640 medium (Canadian Life Technologies) containing 30% WEHI-3B conditioned medium, 1 m hydrocortisone (Sigma Chemical) and 0.36% Sea Plaque agarose (FMC BioProducts, Rockland, ME, USA). Cultures were plated in triplicate 1.5 ml aliquots in 35 mm diameter Petri dishes. Ara-C was added in graded concentrations ranging from 0 to 0.5 m. Colonies of greater than 50 cells were enumerated after 2 to 3 weeks of culture at 37°C and 7% CO 2 . Large colonies were isolated for PCR analysis.
DNA isolation and polymerase chain reaction (PCR)
Genomic DNA was prepared from blood, marrow and spleen cells as well as from individual or pooled hematopoietic colonies utilizing the IDPure Genomic DNA kit (ID Labs Biotechnology, London, Ontario, Canada). Briefly, cells were lysed with a guanidine thiocyanate solution and DNA was adsorbed on silica gel and then eluted with TE buffer (10 mmol/l Tris, 1 mmol/1 EDTA, pH 7.4).
Separate PCR reactions were performed with three distinct sets of primers. To detect the MFG-CD construct, the sense oligonucleotide 5Ј GGT GGA CCA TCC TCT AGA CTG 3Ј was used with the antisense oligonucleotide 5Ј AGC AGC TCC TGG ACC GTC ATG 3Ј, for the amplification of a 421 bp fragment. To verify the presence of an internal standard, a 363 bp ␤-globin product was amplified using the primers 5Ј GAA GTT GGG TGC TTG GAG AC 3Ј (sense) and 5Ј GGA AGG TTG AGC AGA ATA GC 3Ј (antisense). To determine the origin of cells given that male mice served as donors for female recipients, sense primer 5Ј CTC CTG ATG GAC AAA CTT TAC G 3Ј and antisense primer 5Ј TGA GTG CTG ATG GGT GAC GG 3Ј were employed for amplification of a 444 bp Y-chromosome fragment. 29 For the PCR reaction, genomic DNA was subjected to an initial denaturation at 94°C for 2 min, followed by amplification for 40 cycles, each including denaturation at 94°C for 30 s, annealing at 57°C for 30 to 45 s, and extension at 72°C for 30 to 90 s, and a single cycle elongation step at 72°C for 5 min. The reaction mixture (25 or 50 l) contained 1.25 units of Taq polymerase (Pharmacia, Baie d'Urfé, Quebec, Canada, or ID Proof; ID Labs). Resulting PCR products were resolved by 2% agarose gel electrophoresis, visualized by ethidium bromide staining and photographed under UV light.
Enzyme assay
Bone marrow, spleen and blood cells were assayed for CD activity as described previously. 30 The cells (0.5 to 15 × 10 6 ) were washed in phosphate-buffered saline (PBS), suspended in Tris-HCl (5 mm, pH 7.4) and dithiothreiotol (5 mm), and rapidly freeze-thawed three times. The cytosolic extract was recovered in the supernatant following high speed centrifugation. For the enzyme assay, the cytosol was placed in a mixture containing 50 mm TrisHCl and 0.5 Ci 3 H-cytidine (ICN Biomedicals, Irvine, CA, USA). The reaction was incubated for 30 min at 37°C and then stopped with cold HCl (0.001 N). The mix was poured on to Whatman P-81 phosphocellulose discs and the radioactivity bound assessed by scintillation counting. Under these conditions, cytosine nucleosides bind to the filter, but not the deaminated uracil nucleosides. One unit of CD activity was defined as the quantity of enzyme that catalyzes the deamination of 1 nmol of 3 Hcytidine per min at 37°C. Total protein concentration was measured using the Bio-Rad protein assay (Bio-Rad Laboratories, Mississauga, Ontario, Canada).
